Last reviewed · How we verify
placebo and tramadol
Tramadol is a synthetic opioid analgesic that inhibits reuptake of norepinephrine and serotonin while also acting as a weak mu-opioid receptor agonist to provide pain relief.
Tramadol is a synthetic opioid analgesic that inhibits reuptake of norepinephrine and serotonin while also acting as a weak mu-opioid receptor agonist to provide pain relief. Used for Moderate pain management.
At a glance
| Generic name | placebo and tramadol |
|---|---|
| Also known as | placebo, Ultram |
| Sponsor | University of Southern Denmark |
| Drug class | Opioid analgesic with monoamine reuptake inhibition |
| Target | Mu-opioid receptor; norepinephrine transporter; serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Tramadol works through dual mechanisms: it binds to mu-opioid receptors in the central nervous system to produce analgesia, and it also inhibits the reuptake of norepinephrine and serotonin, enhancing their analgesic effects. This combination of opioid and monoamine reuptake inhibition makes it effective for moderate pain management. The placebo component in this study serves as a control comparator.
Approved indications
- Moderate pain management
Common side effects
- Nausea
- Dizziness
- Constipation
- Headache
- Somnolence
- Vomiting
- Seizures
Key clinical trials
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor (PHASE4)
- Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy (PHASE3)
- Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain (NA)
- Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics (PHASE1, PHASE2)
- A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery (PHASE2, PHASE3)
- Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy (PHASE3)
- A Study to Evaluate the Efficacy and Safety of HR18042 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo and tramadol CI brief — competitive landscape report
- placebo and tramadol updates RSS · CI watch RSS
- University of Southern Denmark portfolio CI